[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR030612A1 - Procedimiento e intermedios - Google Patents

Procedimiento e intermedios

Info

Publication number
AR030612A1
AR030612A1 ARP010104219A ARP010104219A AR030612A1 AR 030612 A1 AR030612 A1 AR 030612A1 AR P010104219 A ARP010104219 A AR P010104219A AR P010104219 A ARP010104219 A AR P010104219A AR 030612 A1 AR030612 A1 AR 030612A1
Authority
AR
Argentina
Prior art keywords
intermediates
procedure
preparing
derivatives
maitansinoid
Prior art date
Application number
ARP010104219A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR030612A1 publication Critical patent/AR030612A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Procedimientos para preparar derivados de N-metil-L-alanina y nuevos intermedios del procedimiento. Los derivados e intermedios son utiles para preparar complejos de agente de union a las células maitansinoide.
ARP010104219A 2000-09-12 2001-09-05 Procedimiento e intermedios AR030612A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12

Publications (1)

Publication Number Publication Date
AR030612A1 true AR030612A1 (es) 2003-08-27

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104219A AR030612A1 (es) 2000-09-12 2001-09-05 Procedimiento e intermedios

Country Status (11)

Country Link
US (2) US6570024B2 (es)
EP (1) EP1322597B1 (es)
JP (1) JP4886961B2 (es)
AR (1) AR030612A1 (es)
AT (1) ATE555078T1 (es)
AU (1) AU2001294549A1 (es)
CY (1) CY1112871T1 (es)
DK (1) DK1322597T3 (es)
ES (1) ES2383792T3 (es)
PT (1) PT1322597E (es)
WO (1) WO2002022554A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP4414142B2 (ja) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
EA013323B1 (ru) * 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
KR20180056805A (ko) 2009-06-04 2018-05-29 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
EP3956332B1 (en) * 2019-04-18 2023-02-22 Indena S.p.A. Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS61112042A (ja) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk 架橋試薬として適当な化合物
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (ja) * 1998-07-17 2003-05-19 大日本製薬株式会社 スルトプリド誘導体及び抗スルトプリド抗体
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
JP2004509094A (ja) 2004-03-25
DK1322597T3 (da) 2012-07-02
US20040014980A1 (en) 2004-01-22
WO2002022554A1 (en) 2002-03-21
US6570024B2 (en) 2003-05-27
CY1112871T1 (el) 2016-04-13
US20020156318A1 (en) 2002-10-24
EP1322597B1 (en) 2012-04-25
ATE555078T1 (de) 2012-05-15
ES2383792T3 (es) 2012-06-26
EP1322597A4 (en) 2005-10-19
US6884874B2 (en) 2005-04-26
AU2001294549A1 (en) 2002-03-26
EP1322597A1 (en) 2003-07-02
PT1322597E (pt) 2012-06-01
JP4886961B2 (ja) 2012-02-29

Similar Documents

Publication Publication Date Title
AR030612A1 (es) Procedimiento e intermedios
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
UY27098A1 (es) Derivados de indol
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
PT1459751E (pt) (s,s)-reboxetina para tratar as enxaquecas
ES2150157T3 (es) Piridinas 2-aril sustituidas.
MX9700885A (es) Nuevas heteroariloxazolidinonas.
NO970210L (no) Heteroatomholdige cyklopentanopyridyl-oksazolidinoner
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
GB9818916D0 (en) Use
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
PT983272E (pt) Nova classe de compostos fotoactivos derivados de benzoporfirina
ES2159488B1 (es) Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
DE50101479D1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
NO20014585L (no) Perfluoralkylamider, deres fremstilling og deres anvendelse innen diagnostikken
AR005619A1 (es) Procedimiento para preparar compuestos dicetonicos
UY26265A1 (es) Compuestos calciolíticos
AR005704A1 (es) Heteroariloxazolidinonas
ES2185837T3 (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
EP1150676A4 (en) ACYL DERIVATIVES OF 4-DEMETHYLPENCLOMEDIN, USE AND PREPARATION THEREOF
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas
ES2025222B3 (es) Compuestos azoicos hidrosolubles, procedimiento para su obtencion y su aplicacion como colorantes.

Legal Events

Date Code Title Description
FB Suspension of granting procedure